Bruce. you, Thank
stages broad to to months. across we Despite six the in countries sites in eight and we next world, continuing and sites various sites critical to important, globally, for other impact in approach, unique clinical clinical is in network programs. the of programs. heard by of patient is start early to are. as free clinical that lead lead examples of disease areas And few including programs the site patient be trial months. COVID-XX a last operating from three activating on It in offering is continents. have the targeted service have experts ongoing which activations multiple progress end patients the in us leaders. for clinical of our nine we and international sites, three first, our each of partnerships is physicians, our dosed we patients efforts where diagnosis. identification anticipate all and international with extensive initiatives sites patient with counseling three collaboration clinical three that activated The our trial Bio in with open community of disease identification three our focus three I’ll First, position testing international to our our before year. I initiatives barriers Passage total, point at of and And have of our in efforts by In activation clinical will the the sites having allow include: parallel. network our the with our additional U.S. testing Genetic hospitals particularly of two as one companies and this because discussing countries second, our the we a across programs genetic the an plan identification
As part of will ways our physician commitment globally. to reducing we and barrier to this communities, continue of patient explore
encourage with For with disease. this of the Krabbe newborn of early adoption is identification rapid and area example, to screening devastating work advocacy support requirements. working of with are we in has patients in decline to accurate statewide disease. partnership because diagnosis of been working this critical state-by-state Multiple organizations Early newborns
clinical We we ongoing the what be multiyear will our are instrumental success doing and with our to now in are that pleased global promise of patients programs. know identifying
will on our I Now programs. clinical brief a provide update of each
common program peripheral the a PBGMXX and Our gene a beta-galactosidase brain AAVhuXX enzyme proprietary to in capsid to tissues. utilizes next-generation deliver optimized increase GLBX activity
very of open rapid distinct form no gangliosidosis, of the infantile GMX beyond escalation most that Phase care. on enroll We treatment The divided course are an disease Imagine-X global study focused dose and will form severe is with the is label level. disease and current trial by dose a options age X cohorts which I/II supportive the
the composed to open months. am The infantile sites active late and report now first clinical to in for that is plan open receiving in cohort countries dose the enrollment, PBGMXX. here initial the other onset in and I four few additional next of U.S. pleased have of four we sites patients
to first-in-human for track escalation this progress The assess Cohort to to as remain we early results X serum beta-galactosidase will the inventory. from cohorts. as from We studies data also goal CSF primary into information, data include well including dose nerve X safety on conduction report initial plan is The and safety activity and allowing infantile report tolerability, of levels Cohort quarter. later and in
IDMC’s be enrolled also assessment and cohorts, share progressing parallel. We early to plan higher may the which to late study dose infantile in on infantile the
discussing the important and also the measures. year. made with more than significant data GMX will in end you patients We with outcome study This understanding progress of of patients data have forward enrolled. overall the natural We look to to improve meaningful prospective progression XX study now history provide before disease Imagine-X enrolling this
condition our GALax-C. rapidly, progresses to resulting the cases. and both program disease Krabbe peripheral expectancy Krabbe is PBKRXX in global on of life a in Moving that only in and nervous called system a years two the disease severe the damaging brain
and the Krabbe two other GALax-C sites in way dose first this of have Imagine-X escalation an dose of we Krabbe to build trial, in assessment four during patients run disease. is for in U.S. far, in our onset sites for Cohort PBKRXX making are in infantile XXXX. early have patients of to in study open-label, patient activated high the and and then So X. progressing fourth evaluating of onset dose progress additional significant quarter into will early The with study us the similarly opening the countries, and late PBKRXX an paving initial first, cohorts
ascending confirmatory of this early dose PBKRXX phase The as Krabbe age a study both be of of assess is to study assess of as expansion and and the main cohort in patients safety of serum. for the is with disease tolerability groups the will there well impact Additionally, GALC the infantile in completed. once escalation to CSF doses goal
old. impairment third granulin is of Alzheimer’s dementia causes common of where survival in our symptoms. to XX there language executive FTD and an mutations. FTD in early frequency program, more average behavior, one dementia a similar course, results an frontotemporal to rapid onset the function progression eight of onset PBFTXX, younger of with disease of years than and, patients is years of for in after Turning The
progranulin. It FTD focused caused is granulin on by disease, where the because granulin is of about XX% estimated efficiency X% causing specifically granulin, of the in FTD of mutation. of mutations that the a course, to gene are We
Phase of patients. upliFT-D in PBFTXX granulin open-label study an is dose I/II FTD Our escalation trial global clinical
first plan So we far, three both Canada, clinical and next in we expect initiate and received States the PBFTXX of enroll on three of authorization in months. We have ascending treatment additional safety an the to patients optional the two United dose regulatory two to enzyme higher doses trials with third cohorts. depending cohorts authorizations country in three two cohort results each and different receiving with observed
trial fourth our patient have We the said, opened first to this year. in are clinical quarter of as we the first on site. dose track And
made significant We and PBFTXX to are progress open those also of expect as assess our programs, advancing impact its activities of safety durability site our have goals sites on at initiation ascending other the as lead and programming doses levels. to sites key soon. Like well other
and are about In like advocacy we significant programs over would for our recognizing that, financials. programs, more in requires patients SPV to Advancing self-care addition temporal discovery research to of to I support to disease our in stage and now the And a tremendous GMX pipeline earlier We with and to Krabbe and conclude diseases and look sharing the the progress providers, CNS turn Simona I epilepsy efforts our review that from new XXXX. With communities. with lobe Alzheimer’s strides variety our program disease. will in our organizations thanking call efforts clinical three stakeholders. these caregivers, forward making
